SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001140361-20-010142
Filing Date
2020-04-29
Accepted
2020-04-29 16:31:47
Documents
5
Period of Report
2020-06-17
Effectiveness Date
2020-04-29

Document Format Files

Seq Description Document Type Size
1 DEF 14A nc10011036x2_def14a.htm DEF 14A 1071165
2 logo_cytomx.jpg GRAPHIC 35885
3 nc10011036x1_pc01.jpg GRAPHIC 541667
4 nc10011036x1_pc02.jpg GRAPHIC 559589
5 nc10011036x2_image01.jpg GRAPHIC 281510
  Complete submission text file 0001140361-20-010142.txt   3025364
Mailing Address 151 OYSTER POINT BLVD. SUITE 400 SOUTH SAN FRANCISCO CA 94080
Business Address 151 OYSTER POINT BLVD. SUITE 400 SOUTH SAN FRANCISCO CA 94080 650.515.3185
CytomX Therapeutics, Inc. (Filer) CIK: 0001501989 (see all company filings)

IRS No.: 273521219 | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-37587 | Film No.: 20830825
SIC: 2834 Pharmaceutical Preparations